RNPC3 and systemic sclerosis: In addition to these classical markers, novel SSc‐related autoantibodies have been described such as anti‐eIF2B, anti‐RuvBL1/2, anti‐U11/U12 RNP (RNPC3) and anti‐BICD2 in up to 10% of so‐called ‘seronegative’ patients, often associated with aggressive or overlapping disease phenotypes, including ILD, myopathy, severe GI or myocardial involvement and, in the case of RNPC3 and eIF2B, possible paraneoplastic syndromes.87